Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ORIC · Why this verdict
Why Oric Pharmaceuticals (ORIC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts carry average price targets implying 141% upside from the current price of $8.40 to a target of $17.65, reflecting strong institutional conviction in the clinical pipeline's value. Sentiment breakdown | At least 1 significant clinical data readout occurs in the next 12 months that supports or exceeds analyst expectations, keeping the consensus target above $15. | →Stable |
| CounterAnalyst targets for pre-revenue biotechs are highly speculative and can collapse to near zero on a single negative clinical trial result. | ||
Short interest stands at 21% of float, indicating that a large share of active participants are positioned for the stock to decline, reflecting skepticism about the clinical pipeline's probability of success. Key risks | Short interest falls below 15% within 12 months following positive trial data or a partnership announcement. | →Stable |
| CounterExtremely high short interest in a small-cap biotech creates significant short-squeeze potential if a clinical catalyst delivers positive results. | ||
The company has a Piotroski F-Score of only 2/9, negative free cash flow, and zero revenues, with quality scoring 1.2 against a 4.0 minimum threshold, placing it below the investable quality floor. Quality breakdown | Quality score rises above 4.0 if the company announces a partnership, licensing deal, or achieves a clinical milestone within 12 months. | →Stable |
| CounterPre-clinical and early clinical biotechs necessarily operate below quality thresholds; the relevant metric is pipeline progress, not current financial ratios. | ||
With a market capitalization of $870 million below the $1 billion investability minimum, the stock is formally outside the investable universe by the screening criteria applied. Warnings | Market capitalization rises above $1 billion within 12 months following positive clinical or corporate developments. | →Stable |
| CounterMany multi-bagger biotechs are discovered below the $1 billion threshold; excluding them entirely sacrifices early-stage upside. | ||
Analysts carry average price targets implying 141% upside from the current price of $8.40 to a target of $17.65, reflecting strong institutional conviction in the clinical pipeline's value.
→StableSentiment breakdown
- Expectation
- At least 1 significant clinical data readout occurs in the next 12 months that supports or exceeds analyst expectations, keeping the consensus target above $15.
CounterAnalyst targets for pre-revenue biotechs are highly speculative and can collapse to near zero on a single negative clinical trial result.
Short interest stands at 21% of float, indicating that a large share of active participants are positioned for the stock to decline, reflecting skepticism about the clinical pipeline's probability of success.
→StableKey risks
- Expectation
- Short interest falls below 15% within 12 months following positive trial data or a partnership announcement.
CounterExtremely high short interest in a small-cap biotech creates significant short-squeeze potential if a clinical catalyst delivers positive results.
The company has a Piotroski F-Score of only 2/9, negative free cash flow, and zero revenues, with quality scoring 1.2 against a 4.0 minimum threshold, placing it below the investable quality floor.
→StableQuality breakdown
- Expectation
- Quality score rises above 4.0 if the company announces a partnership, licensing deal, or achieves a clinical milestone within 12 months.
CounterPre-clinical and early clinical biotechs necessarily operate below quality thresholds; the relevant metric is pipeline progress, not current financial ratios.
With a market capitalization of $870 million below the $1 billion investability minimum, the stock is formally outside the investable universe by the screening criteria applied.
→StableWarnings
- Expectation
- Market capitalization rises above $1 billion within 12 months following positive clinical or corporate developments.
CounterMany multi-bagger biotechs are discovered below the $1 billion threshold; excluding them entirely sacrifices early-stage upside.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Oric Pharmaceuticals offers extraordinary asymmetry with analyst price targets implying 141% upside, but the company is pre-revenue, cash-burning, below the $1 billion market cap investability threshold, and carries 21% short interest, making it a high-risk speculative situation outside the normal investable universe.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 5.0 |
- ▸Overbought (RSI 94)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 94 (late-cycle distribution risk)
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 9.9 |
| erm sentiment | 4.9 |
- ▸Analyst upside: 74%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.7 |
| growth rank | 5.0 |
Technical
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 5.6 |
Risk (lower is worse)
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 7.0 |
| debt equity | 3.8 |
- ▸High short interest justified: 21%
- ▸High IV: 200%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 5.5 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.2>=5.5
- ASYMMETRY:3.4>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=7.2>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
3.44
Upside
+51.6%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 94
EdgeInst Constrain — Small cap ($1.2B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 8.0, and Momentum at 7.2; the weakest are Quality at 1.2, Technical at 1.9, and Risk (lower is worse) at 3.2. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 3.44 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Upside 141pct
Trip ifAnalyst consensus price target falls below $12 (below 50% above current price) following negative clinical data.
- P2High Short Interest 21pct
Trip ifShort interest rises above 25% of float.
- P3Cash Burn Quality Floor Breach
Trip ifCash runway falls below 12 months based on quarterly burn rate exceeding $40 million without a financing event.
- P4Below 1b Market Cap Barrier
Trip ifMarket capitalization falls below $500 million.